BPS Bioscience offers products to assess the efficacy of candidate drugs targeting GLP-1
If youd like to explore what these changes could mean for your products, get in touch with the Synergy team today
The GABAergic deficit hypothesis of major depressive disorder
Az rak eltrhetnek a patikk s magnklinikk kztt, de jelents rzuhans ritka
Control, convenience, consequence: how GLP-1 is reshaping eating and shopping As GLP-1 medications slow digestion and increase satiety, users naturally rebalance how they buy and consume food and drinks, boosting the need for: Portion-controlled formats that support structure and predictability Nutrient-dense, functional products that work harder per serving Routine-friendly, practical choices over novelty or impulse Personal care products that support healthy, feel-good transformation Data from YouGovs German FMCG shopper panel (2025) shows early signals of basket adaptations between GLP-1 users, considerers, and the general population